Key facts
- CardioWise’s last known valuation is $33.0M (Jul 2025).
- It has raised $5.7M across 4 recorded rounds; the latest was Seed Round ($340K) in Mar 2020.
- Notable investors include US National Science Foundation, Washington University in St. Louis, Arkansas Development Finance Authority, Arkansas Science & Technology Authority, GE Edison Accelerator — 7 tracked in total.
- CardioWise has filed 8 Form Ds with the SEC since 2012, most recently Sep 2025 ( sold).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for CardioWise
Funding rounds
4 roundsAbout CardioWise
Developer of a non-invasive cardiac CT imaging software designed for speedy quantitative analysis of left ventricular function. The company's software utilizes artificial intelligence algorithms to offer diagnostic insights to physicians by leveraging commonly available clinical images and delivering quantitative and meaningful results, enabling companies to increase objectivity in decision-making and improve day-to-day clinical cardiac practice.
- Sector
- Healthcare
- HQ
- Fayetteville, AR, United States
- Founded
- 2010
- Employees
- 5
- Website
- cardiowiseinc.com/
- Ownership
- Privately Held (backing)
CardioWise doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CardioWise shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CardioWise in its N-PORT filings yet. We sweep new filings monthly.